JP2019512005A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512005A5
JP2019512005A5 JP2018540838A JP2018540838A JP2019512005A5 JP 2019512005 A5 JP2019512005 A5 JP 2019512005A5 JP 2018540838 A JP2018540838 A JP 2018540838A JP 2018540838 A JP2018540838 A JP 2018540838A JP 2019512005 A5 JP2019512005 A5 JP 2019512005A5
Authority
JP
Japan
Prior art keywords
raav
hidua
pharmaceutical composition
patient
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018540838A
Other languages
English (en)
Japanese (ja)
Other versions
JP7360241B2 (ja
JP2019512005A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/016133 external-priority patent/WO2017136500A1/en
Publication of JP2019512005A publication Critical patent/JP2019512005A/ja
Publication of JP2019512005A5 publication Critical patent/JP2019512005A5/ja
Priority to JP2023023041A priority Critical patent/JP2023062088A/ja
Application granted granted Critical
Publication of JP7360241B2 publication Critical patent/JP7360241B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018540838A 2016-02-03 2017-02-02 ムコ多糖症i型を治療するための遺伝子治療 Active JP7360241B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023023041A JP2023062088A (ja) 2016-02-03 2023-02-17 ムコ多糖症i型を治療するための遺伝子治療

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662290547P 2016-02-03 2016-02-03
US62/290,547 2016-02-03
US201662323271P 2016-04-15 2016-04-15
US62/323,271 2016-04-15
US201662337178P 2016-05-16 2016-05-16
US62/337,178 2016-05-16
US201662367798P 2016-07-28 2016-07-28
US62/367,798 2016-07-28
US201762452560P 2017-01-31 2017-01-31
US62/452,560 2017-01-31
PCT/US2017/016133 WO2017136500A1 (en) 2016-02-03 2017-02-02 Gene therapy for treating mucopolysaccharidosis type i

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023023041A Division JP2023062088A (ja) 2016-02-03 2023-02-17 ムコ多糖症i型を治療するための遺伝子治療

Publications (3)

Publication Number Publication Date
JP2019512005A JP2019512005A (ja) 2019-05-09
JP2019512005A5 true JP2019512005A5 (cg-RX-API-DMAC7.html) 2020-03-12
JP7360241B2 JP7360241B2 (ja) 2023-10-12

Family

ID=58108727

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018540838A Active JP7360241B2 (ja) 2016-02-03 2017-02-02 ムコ多糖症i型を治療するための遺伝子治療
JP2023023041A Pending JP2023062088A (ja) 2016-02-03 2023-02-17 ムコ多糖症i型を治療するための遺伝子治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023023041A Pending JP2023062088A (ja) 2016-02-03 2023-02-17 ムコ多糖症i型を治療するための遺伝子治療

Country Status (11)

Country Link
US (3) US10973929B2 (cg-RX-API-DMAC7.html)
EP (1) EP3411488B1 (cg-RX-API-DMAC7.html)
JP (2) JP7360241B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250171426A (cg-RX-API-DMAC7.html)
AU (3) AU2017215211C1 (cg-RX-API-DMAC7.html)
BR (1) BR112018015751A2 (cg-RX-API-DMAC7.html)
CA (1) CA3012195A1 (cg-RX-API-DMAC7.html)
IL (1) IL260959B2 (cg-RX-API-DMAC7.html)
MA (1) MA43968A (cg-RX-API-DMAC7.html)
SG (2) SG10201912758TA (cg-RX-API-DMAC7.html)
WO (1) WO2017136500A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015021036A2 (pt) 2013-03-15 2017-10-10 Univ Pennsylvania composições e métodos para tratar mps1
JP2016523835A (ja) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
MA43968A (fr) 2016-02-03 2018-12-12 Univ Pennsylvania Thérapie génique pour traiter la mucopolysaccharidose de type i
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
RS65241B1 (sr) 2017-02-28 2024-03-29 Univ Pennsylvania Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
BR112019023303A2 (pt) 2017-05-11 2020-06-16 The Trustees Of The University Of Pennsylvania Terapia de gene para lipofuscinoses ceroides neuronais
CA3068328A1 (en) * 2017-07-06 2019-01-10 The Trustees Of The University Of Pennsylvania Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
EP3684938A1 (en) * 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
CN107699590A (zh) * 2017-10-13 2018-02-16 成都中医药大学 一种制备重组人α‑L‑艾杜糖醛酸酶的方法
US11555206B2 (en) 2017-11-30 2023-01-17 The Trustees Of The University Of Pennsylvania Gene therapy for mucopolysaccharidosis IIIA
EA202091352A1 (ru) 2017-11-30 2020-08-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Генотерапия мукополисахаридоза iiib
IL280198B2 (en) * 2018-07-18 2026-01-01 Regenxbio Inc Treatment of mucopolysaccharidosis I with fully glycosylated human iduronidase-alpha-L (idus)
EP3860659A1 (en) 2018-10-01 2021-08-11 The Trustees of the University of Pennsylvania Compositions useful for treating gm1 gangliosidosis
WO2020086893A1 (en) 2018-10-25 2020-04-30 Regeneron Pharmaceuticals, Inc. Methods for analysis of viral capsid protein composition
EP3894864A2 (en) * 2018-12-10 2021-10-20 Denali Therapeutics Inc. Lysosomal storage disorder biomarkers and methods of use thereof
MX2021007600A (es) * 2018-12-21 2021-08-11 Univ Pennsylvania Composiciones para la reduccion de la expresion transgenica especifica de drg.
CA3106693A1 (en) * 2019-02-06 2020-08-13 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type i
MX2021010134A (es) 2019-02-22 2021-09-23 Univ Pennsylvania Virus adenoasociado recombinante para el tratamiento de la neurodegeneracion de inicio en adultos asociada a grn.
JP7697943B2 (ja) * 2019-10-23 2025-06-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 導入遺伝子発現のdrg特異的低減のための組成物
KR20220131522A (ko) * 2020-01-22 2022-09-28 리젠엑스바이오 인크. 완전-인간 글리코실화된 인간 알파-l-이두로니다아제 (idua)를 사용한 점액다당류증 i의 치료
WO2021155337A1 (en) * 2020-02-02 2021-08-05 The Trustees Of The University Of Pennsylvania Compositions useful for treating gm1 gangliosidosis
IL298138A (en) 2020-05-12 2023-01-01 Univ Pennsylvania Compositions for drg-specific reduction of transgene expression
AU2021332331A1 (en) * 2020-08-26 2023-03-09 The Trustees Of The University Of Pennsylvania Recombinant adeno-associated virus for treatment of GRN-associated adult-onset neurodegeneration
AU2021356684A1 (en) 2020-10-09 2023-05-11 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of fabry disease
WO2022094284A1 (en) * 2020-10-30 2022-05-05 Immusoft Corporation Methods of administering genetically modified b cells for in vivo delivery of therapeutic agents
MX2023008826A (es) 2021-02-01 2023-09-15 Regenxbio Inc Terapia génica para lipofuscinosis neuronal ceroidea.
WO2023049846A1 (en) * 2021-09-24 2023-03-30 The Trustees Of The University Of Pennsylvania Compositions useful for treatment of charcot-marie-tooth disease
AU2022379625A1 (en) * 2021-10-27 2024-05-16 The University Of North Carolina At Chapel Hill Aav-idua vector for treatment of mps i
WO2023087019A2 (en) 2021-11-15 2023-05-19 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
US20240408157A1 (en) 2021-12-02 2024-12-12 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of fabry disease
WO2023172975A1 (en) * 2022-03-08 2023-09-14 University Of Massachusetts Methods of raav packaging
US20250250326A1 (en) 2022-04-06 2025-08-07 The Trustees Of The University Of Pennsylvania Passive immunization with anti-aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
CA3247109A1 (en) 2022-04-06 2023-10-12 The Trustees Of The University Of Pennsylvania Compositions and treatment methods for metastatic breast cancer that is human epidermal growth factor receptor 2 positive and other cancers
CN115838709A (zh) * 2022-11-29 2023-03-24 武汉禾元生物科技股份有限公司 以基因工程水稻表达和制备重组人艾杜糖苷酸酶的方法
JP2026522354A (ja) 2023-06-12 2026-07-07 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ムコ多糖症iiibのためのaav遺伝子療法
WO2025007046A1 (en) 2023-06-29 2025-01-02 The Trustees Of The University Of Pennsylvania Mutant aav with central nervous system targeting motifs and compositions containing same
IL326390A (en) 2023-08-10 2026-04-01 Univ Pennsylvania Compositions and methods for treatment of spinal muscular atrophy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149909A (en) 1995-06-23 2000-11-21 Women's And Children's Hospital Synthetic α-L-iduronidase and genetic sequences encoding same
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
WO1999058691A2 (en) 1998-05-13 1999-11-18 Harbor-Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
US6426208B1 (en) 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
RU2196988C2 (ru) 2000-04-19 2003-01-20 Государственный новосибирский областной клинический диагностический центр Способ диагностики мукополисахаридозов
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
AU2003302724A1 (en) 2002-08-13 2004-07-09 Mcivor, Scott, R. Methods of using vectors to treat metabolic disorders
US7155804B2 (en) 2003-09-17 2007-01-02 Moog Inc. Method of forming an electric motor
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US20090062144A1 (en) 2007-04-03 2009-03-05 Nancy Lan Guo Gene signature for prognosis and diagnosis of lung cancer
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
WO2011126808A2 (en) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
DK2561073T3 (en) 2010-04-23 2016-12-12 Univ Massachusetts Aav vectors targeted to central nervous system and methods of use thereof
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
EP2394667A1 (en) 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
CN103502458B (zh) 2011-02-17 2016-11-16 宾夕法尼亚大学托管会 用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法
DK3693025T3 (da) 2011-04-22 2022-01-10 Univ California Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
HUE051612T2 (hu) 2012-07-11 2021-03-01 Sangamo Therapeutics Inc Eljárások és készítmények lizoszomális tárolási betegségek kezelésére
WO2014125647A1 (ja) 2013-02-18 2014-08-21 富士通オプティカルコンポーネンツ株式会社 光受信装置
BR112015021036A2 (pt) 2013-03-15 2017-10-10 Univ Pennsylvania composições e métodos para tratar mps1
JP2016523835A (ja) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
EP3564379A1 (en) 2013-09-13 2019-11-06 California Institute of Technology Selective recovery
WO2016049230A1 (en) 2014-09-24 2016-03-31 City Of Hope Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
CN107002096A (zh) 2014-10-06 2017-08-01 阿罗根有限公司 基于aav的基因疗法
KR20220082100A (ko) 2015-05-15 2022-06-16 리젠츠 오브 더 유니버시티 오브 미네소타 중추 신경계로의 아데노-연관 치료적 전달
CN107922932A (zh) 2015-08-06 2018-04-17 中央研究院 用于酶置换疗法的改造酶
AU2016341428B2 (en) 2015-10-23 2021-12-02 University Of Iowa Research Foundation Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection
EP3992283A1 (en) 2015-12-11 2022-05-04 The Trustees Of The University Of Pennsylvania Scalable purification method for aavrh10
WO2017100674A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav1
EP3387138B2 (en) 2015-12-11 2026-05-27 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
US11015174B2 (en) 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV8
EP3402533B1 (en) 2016-01-15 2021-08-04 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of neurologic disease
MA43968A (fr) 2016-02-03 2018-12-12 Univ Pennsylvania Thérapie génique pour traiter la mucopolysaccharidose de type i
CA3068328A1 (en) 2017-07-06 2019-01-10 The Trustees Of The University Of Pennsylvania Aav9-mediated gene therapy for treating mucopolysaccharidosis type i

Similar Documents

Publication Publication Date Title
JP2019518002A5 (cg-RX-API-DMAC7.html)
US12370268B2 (en) Fabry disease gene therapy
Pipe et al. Clinical considerations for capsid choice in the development of liver-targeted AAV-based gene transfer
JP6767483B2 (ja) 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター
Choudhury et al. In vivo selection yields AAV-B1 capsid for central nervous system and muscle gene therapy
JP7532360B2 (ja) ウィルソン病を処置するための組成物および方法
JP2023036618A (ja) コロイデレミアの遺伝子治療に使用するためのaavベクター
JP2023106497A (ja) 減少した免疫反応性を有するaavビリオン、およびその使用
JP2023538129A (ja) 好ましい発現レベルを有するアデノ随伴ウイルス組成物
JP6978407B2 (ja) Glp−1及び代謝性疾患を治療するための組成物におけるその使用
JP7061067B2 (ja) クリグラー・ナジャー症候群の処置のための組成物
JP2018537984A (ja) 脊髄性筋萎縮症の処置において有用なアデノ−関連ウイルスベクター
JP2022116045A (ja) アルデヒドデヒドロゲナーゼ欠損症の治療のための遺伝子治療
JP2020503265A (ja) メチル−cpg結合タンパク質2をコードする組換えアデノ随伴ウイルスの髄腔内送達
JP2023526498A (ja) グルコース-6-ホスファターゼ(G6Pase-a)をコードする遺伝子治療用ベクター
US20250161493A1 (en) Compositions and methods for in vivo nuclease-mediated treatment of ornithine transcarbamylase (otc) deficiency
WO2024060463A1 (zh) 改进的人凝血因子viii基因表达盒及其应用
US20230340526A1 (en) Novel aav3b variants that target hepatocytes and evade the humoral immune response
JP2023545384A (ja) 中枢神経系または筋肉送達のための組換えアデノ随伴ウイルス
WO2025039622A1 (zh) 经修饰的腺相关病毒载体及其在治疗中枢神经系统疾病中的用途
WO2023060272A2 (en) Recombinant adeno-associated viruses for cns tropic delivery
CN121175424A (zh) 一种携带smn基因表达框的病毒载体及其用途
BR112017027956B1 (pt) Vetores de vírus adenoassociado recombinante, uso e método de produção dos mesmos, e composição farmacêutica